Production and Release of Neuroprotective Tumor Necrosis Factor by P2X7Receptor-Activated Microglia
Open Access
- 7 January 2004
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 24 (1) , 1-7
- https://doi.org/10.1523/jneurosci.3792-03.2004
Abstract
After a brain insult, ATP is released from injured cells and activates microglia. The microglia that are activated in this way then release a range of bioactive substances, one of which is tumor necrosis factor (TNF). The release of TNF appears to be dependent on the P2X7 receptor. The inhibitors 1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio]butadiene (U0126), anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), and 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)IH-imidazole (SB203580), which target MEK (mitogen-activated protein kinase kinase), JNK (c-Jun N-terminal kinase), and p38, respectively, all potently suppress the production of TNF in ATP-stimulated microglia, whereas the production of TNF mRNA is strongly inhibited by U0126 and SP600125. SB203580 did not affect the increased levels of TNF mRNA but did prevent TNF mRNA from accumulating in the cytoplasm. The ATP-provoked activation of JNK and p38 [but not extracellular signal-regulated kinase (ERK)] could be inhibited by brilliant blue G, a P2X7 receptor blocker, and by genistein and 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine, which are general and src-family-specific tyrosine kinase inhibitors, respectively. Most important, we found that treatment of the microglia in neuron-microglia cocultures with the P2X7 agonist 2′-3′-O-(benzoyl-benzoyl) ATP led to significant reductions in glutamate-induced neuronal cell death, and that either TNF-α converting enzyme inhibitor or anti-TNF readily suppressed the protective effect implied by this result. Together, these findings indicate that both ERK and JNK are involved in the regulation of TNF mRNA expression, that p38 is involved in the nucleocytoplasmic transport of TNF mRNA, and that a PTK (protein tyrosine kinase), possibly a member of the src family, acts downstream of the P2X7 receptor to activate JNK and p38. Finally, our data suggest that P2X7 receptor-activated microglia protect neurons against glutamate toxicity primarily because they are able to release TNF.Keywords
This publication has 34 references indexed in Scilit:
- P2X7 receptor activates extracellular signal-regulated kinases ERK1 and ERK2 independently of Ca2+ influxBiochemical Journal, 2003
- Microglial activation by purines and pyrimidinesGlia, 2002
- Rapid Secretion of Interleukin-1β by Microvesicle SheddingImmunity, 2001
- Mitogen-Activated Protein Kinase p38 Controls the Expression and Posttranslational Modification of Tristetraprolin, a Regulator of Tumor Necrosis Factor Alpha mRNA StabilityMolecular and Cellular Biology, 2001
- ATP-stimulated Release of Interleukin (IL)-1β and IL-18 Requires Priming by Lipopolysaccharide and Is Independent of Caspase-1 CleavageJournal of Biological Chemistry, 2001
- SAPK/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptorJournal of Biological Chemistry, 2000
- Pharmacology of Cloned P2X ReceptorsAnnual Review of Pharmacology and Toxicology, 2000
- Tumor Necrosis Factor-αStroke, 1997
- Purinergic Modulation of Interleukin-1β Release from Microglial Cells Stimulated with Bacterial EndotoxinThe Journal of Experimental Medicine, 1997
- Identification of Elastase as a Secretory Protease from Cultured Rat MicrogliaJournal of Neurochemistry, 1992